Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients (Q40137556)
Jump to navigation
Jump to search
scientific article published on January 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients |
scientific article published on January 2008 |
Statements
1 reference
Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients (English)
1 reference
1 reference
Jose Baselga
1 reference
Gunnar Folprecht
1 reference
Claus-Henning Köhne
1 reference
Charles Zacharchuk
1 reference
Luis Paz-Ares
1 reference
Federico Rojo
1 reference
Susan Quinn
1 reference
Esther Casado
1 reference
Ramon Salazar
1 reference
Richat Abbas
1 reference
Chantal Lejeune
1 reference
Irene Marimón
1 reference
Jordi Andreu
1 reference
Ulrike Ubbelohde
1 reference
Hernan Cortes-Funes
1 reference
1 January 2008
1 reference
1 reference
Identifiers
1 reference